Testicular cancer clinical practice guidelines in oncology

Robert J. Motzer, Graeme B. Bolger, Barry Boston, Michael A. Carducci, Mayer Fishman, Steven L. Hancock, Ralph J. Hauke, Gary R. Hudes, Eric Jonasch, Philip Kantoff, Timothy M. Kuzel, Paul H. Lange, Ellis G. Levine, Chris Logothetis, Kim A. Margolin, Kamal S. Pohar, Bruce G. Redman, Cary N. Robertson, Wolfram E. Samlowski, Joel Sheinfeld

Research output: Contribution to journalArticlepeer-review

16 Scopus citations

Abstract

An estimated 8250 new cases of testicular cancer will be diagnosed in the United States in 2006, with germ cell tumors (GCTs) constituting 95% of the malignant tumors arising in the testes. Although GCTs are relatively uncommon tumors, they are the most common solid tumor in men between the ages of 15 and 34 years. The worldwide incidence of these tumors has more than doubled in the past 40 years. More than 90% of all patients diagnosed with GCTs are cured, including 70% to 80% of patients with advanced tumors who are treated with chemotherapy. Standard therapy has been established at essentially all stages of management and must be closely followed to ensure the potential for cure.

Original languageEnglish (US)
Pages (from-to)1038-1058
Number of pages21
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume4
Issue number10
DOIs
StatePublished - Nov 2006

Keywords

  • Alpha-fetoprotein
  • Cisplatin
  • Germ cell tumors
  • Human chorionic gonadotropin
  • Lactate dehydrogenase
  • NCCN clinical practice guidelines
  • Nonseminoma
  • Seminoma
  • Testicular cancer

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Testicular cancer clinical practice guidelines in oncology'. Together they form a unique fingerprint.

Cite this